Thyroid arsenic content and papillary thyroid carcinoma arising 10 years after oral arsenic trioxide therapy for refractory acute promyelocytic leukemia

Leuk Lymphoma. 2014 May;55(5):1184-5. doi: 10.3109/10428194.2013.837161. Epub 2013 Sep 23.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use*
  • Arsenic Trioxide
  • Arsenicals / adverse effects*
  • Arsenicals / therapeutic use
  • Carcinoma / diagnosis
  • Carcinoma / etiology*
  • Carcinoma, Papillary
  • Female
  • Humans
  • Leukemia, Promyelocytic, Acute / complications*
  • Leukemia, Promyelocytic, Acute / drug therapy
  • Neoplasms, Second Primary / diagnosis
  • Neoplasms, Second Primary / etiology*
  • Oxides / adverse effects*
  • Oxides / therapeutic use
  • Thyroid Cancer, Papillary
  • Thyroid Gland / metabolism
  • Thyroid Neoplasms / diagnosis
  • Thyroid Neoplasms / etiology*
  • Young Adult

Substances

  • Antineoplastic Agents
  • Arsenicals
  • Oxides
  • Arsenic Trioxide